Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th
March 25, 2025 16:05 ET | Source: Sight Sciences, Inc. MENLO PARK,…
reAlphas AiChat Unveils Next-Gen AI Agents
DUBLIN, Ohio, March 03, 2025 (GLOBE NEWSWIRE) -- reAlpha Tech Corp. (“reAlpha”…
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
February 28, 2025 17:00 ET | Source: Keros Therapeutics, Inc. LEXINGTON, Mass.,…
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Topline data from Phase 3 ONWARD trials for Alumis’ ESK-001 in moderate-to-severe…
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025
US Bankruptcy Court for the Southern District of Texas issued an order…
Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of Circular RNA
Hamilton, Bermuda, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Further proof of great…
Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial
December 12, 2024 06:00 ET | Source: Keros Therapeutics, Inc. Keros will…
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
MALVERN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or…
Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041
COMMACK, NY and TAMPA, FL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- SCIENTURE,…
Continuity Biosciences Launches to Enable Breakthrough Therapies with Innovative Delivery Technologies
BRADENTON, Fla. and HOUSTON, Nov. 13, 2024 /PRNewswire/ -- Continuity Biosciences, LLC,…
